Physician profile
Jolly Thomas
NPI 1992717417
$810.22
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $414.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $359.18 | 2019-2020 | |
| Novo Nordisk INC | $83.75 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $82.64 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.77 | 2019-2020 | |
| Lilly USA, LLC | $62.75 | 2020 | |
| Amarin Pharma, INC. | $54.53 | 2020 | |
| Glaxosmithkline, LLC. | $48.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.70 | 2019 | |
| Esperion Therapeutics, INC. | $18.24 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jolly Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.